Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Compass TherapeuticsCMPX -0.51%23 Cash-to-Debt is 19.88 as of Mar. 2026, which is 3% below its 10-year median of 20.57. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, Compass Therapeutics ranks better than 62.1% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Compass Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2026 was 19.88.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Compass Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Compass Therapeutics's Cash-to-Debt or its related term are showing as below:
CMPX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.7 Med: 20.57 Max: 134.4
Current: 19.88
During the past 8 years, Compass Therapeutics's highest Cash to Debt Ratio was 134.40. The lowest was 1.70. And the median was 20.57.
CMPX's Cash-to-Debt is ranked better than 62.1% of 1401
companies
in the Biotechnology industry
Industry Median: 6.48
vs CMPX: 19.88
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Compass Therapeutics Cash-to-Debt Related Terms
Compass Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Compass Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Compass Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics (CMPX) has a Cash-to-Debt of 19.88 as of Mar. 2026. This is near median its historical median of 20.57. Over the past decade, Compass Therapeutics' Cash-to-Debt has ranged from 1.70 to 134.40. According to the industry distribution chart, Compass Therapeutics ranks #531 out of 1401 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Compass Therapeutics' Cash-to-Debt too high?
Compass Therapeutics' current Cash-to-Debt of 19.88 is near median its 10-year median of 20.57. Over the past 10 years, this metric has ranged from a low of 1.70 to a high of 134.40. The Biotechnology industry median Cash-to-Debt is 6.48. Compass Therapeutics' value of 19.88 is 206.8% above this industry median. Based on the distribution chart, Compass Therapeutics ranks #531 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Cash-to-Debt compare to CCCC and AVIR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #531 out of 1401 companies for Cash-to-Debt. This puts Compass Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.48. Compass Therapeutics' value of 19.88 is 206.8% above this benchmark. Historically, Compass Therapeutics' own Cash-to-Debt has ranged from 1.70 to 134.40 over the past decade. While the company's 10-year median is 20.57 vs. the industry median of 6.48, Compass Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.48, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compass Therapeutics's current Cash-to-Debt of 19.88 is 206.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Therapeutics's current Cash-to-Debt is 19.88, which is near median its own 10-year median of 20.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Cash-to-Debt of 19.88. The current Cash-to-Debt is 19.88, which is near median its 10-year median of 20.57 and 206.8% above the Biotechnology industry median of 6.48. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Cash-to-Debt is 19.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score
Get the complete analysis for CMPX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPX has been successfully added to your 
